Lisa A. Cooper, MD, MPH, of Johns Hopkins University School of Medicine; Clyde W. Yancy, MD, MSc, of Northwestern University, and David R. Williams, PhD, MPH, of Harvard T.H. Chan School of Public Health, join JAMA Editor in Chief Howard Bauchner, MD, to discuss racism and structural racism in health care and medicine. Recorded March 16, 2021.

Interview with Thomas R. Frieden, MD, MPH, author of National Initiatives to Prevent Myocardial Infarction and Stroke

Interview with Michael J. Barry, MD, author of USPSTF Recommendation—Screening for Lung Cancer

Genetic variants of the SARS-CoV-2 virus are emerging but so far do not seem to have caused breakthrough infections in people with previous infection or in those who have been vaccinated. John P. Moore, PhD, of Weill Medical College of Cornell University in New York, joins JAMA's Q&A series for an update on the latest variants and what you need to know. Recorded March 4, 2021.

Related Article:

Approaches for Optimal Use of Different COVID-19 Vaccines

Interview with Christopher J.L. Murray, MD, DPhil, author of The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection?

Nancy E. Messonnier, MD is director of the National Center for Immunization and Respiratory Diseases (NCIRD) at the Centers for Disease Control and Prevention (CDC) and leads the CDC's efforts on COVID-19 vaccination. She joins JAMA's Q&A series to discuss the agency's response to emerging coronavirus variants, the FDA advisory hearings on the new Johnson & Johnson vaccine, and other agency activities and priorities related to COVID-19 control. Recorded February 26, 2021.

Related Content:

• Genetic Variants of SARS-CoV-2—What Do They Mean?
• Coronavirus Vaccine Update From the CDC With Nancy E. Messonnier, MD
• SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants
• Experts Discuss COVID-19—Vaccine Doses, Virus Variants, and More
• Emergence of a Novel SARS-CoV-2 Variant in Southern California
• SARS-CoV-2 Variants of Concern in the United States
• Pregnant People Getting Mixed Messages About COVID-19 Vaccines
• The Johnson & Johnson Vaccine for COVID-19
• SARS-CoV-2 Viral Variants—Tackling a Moving Target
• Vaccine Distribution—Equity Left Behind?
• Taking Vaccine to Where the Virus Is—Equity and Effectiveness in Coronavirus Vaccinations?

Interview with James C. Robinson, PhD, author of Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic

Interview with Richard Saitz, MD, author of Removing One Barrier to Opioid Use Disorder Treatment: Is It Enough and with Yngvild Olsen, MD, author of Overcoming Barriers to Treatment of Opioid Use Disorder

Interview with Ik-Kyung Jang, MD, PhD, author of New Insights Into Plaque Erosion as a Mechanism of Acute Coronary Syndromes

CDC Director Rochelle P. Walensky, MD, MPH, returns to JAMA's Q&A series to discuss the agency's response to emerging SARS-CoV-2 variants, implications for the planned vaccine mobilization strategy, the upcoming Johnson & Johnson vaccine FDA advisory hearings, strategies for reopening K-12 schools, and other agency activities and priorities related to COVID-19 control. Recorded February 17, 2021.

Related Article(s):

• Coronavirus Update With CDC Director Rochelle Walensky - February 17, 2021
• SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities
• SARS-CoV-2 Viral Variants—Tackling a Moving Target